OBJECTIVES: To evaluate patient and physician satisfaction with risperidone long-acting injection (RLAI) in patients enrolled in the electronic Schizophrenia Treatment Adherence Registry (e-STAR) in Korea.METHODS: e-STAR is an ongoing, international, long-term, prospective, observational study of schizophrenia patients who start RLAI during their routine clinical management. Data are collected for 1-year retrospectively and at 3-monthly intervals for 2-years prospectively. Both patient and physician satisfaction with treatment is assessed on a 5-point scale from ‘very good’ to ‘very bad’ at baseline and every visit thereafter.RESULTS: To date, 162 patients enrolled in e-STAR from Korea and 127 were followed for 6-month; of which 107 with baseline and at least one follow-up for treatment satisfaction assessment were included in this interim analysis. Mean age was 36.8±11.4 years, 49.5% were male and mean time since diagnosis was 8.4±7.1 years. Mean dose of RLAI was 28.0 mg at baseline and 32.8 mg at 6-months. At 6-months, 82.2% (88/107) still continued on RLAI. For all 107 patients, 37.4% of patients expressed “good” or “very good” satisfaction while 22.4% of them expressed “bad” or “very bad” with their previous treatment at baseline. Similarly, 46.8% of physicians reported “good” or “very good” of satisfaction and 17.7% rated their satisfaction as “bad” or “very bad” at baseline. After initiating RLAI, both patient and physician satisfaction with treatment improved. At 6-months after start of RLAI, 71.1% of patients were highly satisfied (‘good’ or ‘very good’) with this treatment and 7.5% felt ‘bad’ or ‘very bad’. Physicians also expressed high satisfaction with RLAI with 77.6% reporting ‘good’ or ‘very good’ and 1.9% reported below ‘moderate’.CONCLUSIONS: This interim analysis indicates that after RLAI treatment, both patient and physician satisfaction with the treatment substantially improved. High satisfaction might lead to better adherence and thus better long-term treatment outcomes.